RVNC - Revance Therapeutics Inc Stock Price, Fair Value and News

3.81USD-0.16 (-4.03%)Market Closed

Market Summary

USD3.81-0.16

Market Closed

-4.03%

RVNC Alerts

JPMORGAN CHASE & CO reported owning 2.6% of RVNC [2024-04-09]

1 major insider buys recently.

RVNC Stock Price

View Fullscreen

RVNC RSI Chart

RVNC Valuation

Market Cap

336.1M

Price/Earnings (Trailing)

-1.04

Price/Sales (Trailing)

1.44

Price/Free Cashflow

-1.5

RVNC Price/Sales (Trailing)

RVNC Profitability

Return on Equity

213.71%

Return on Assets

-67.72%

Free Cashflow Yield

-66.49%

RVNC Fundamentals

RVNC Revenue

Revenue (TTM)

234.0M

Rev. Growth (Yr)

39.82%

Rev. Growth (Qtr)

22.94%

RVNC Earnings

Earnings (TTM)

-324.0M

Earnings Growth (Yr)

61.84%

Earnings Growth (Qtr)

60.55%

Breaking Down RVNC Revenue

Last 7 days

-18.8%

Last 30 days

-28.1%

Last 90 days

-37.1%

Trailing 12 Months

-87.3%

How does RVNC drawdown profile look like?

RVNC Financial Health

Current Ratio

3.8

Debt/Equity

-2.81

Debt/Cashflow

-0.51

RVNC Investor Care

Shares Dilution (1Y)

6.54%

Diluted EPS (TTM)

-3.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	156.6M	186.4M	214.2M	234.0M
2022	89.8M	99.3M	108.6M	132.6M
2021	28.6M	47.1M	63.0M	77.8M
2020	4.1M	7.9M	11.6M	15.3M
2019	4.3M	4.8M	5.1M	413.0K
2018	2.4M	3.1M	4.0M	3.7M
2017	1.2M	1.2M	963.0K	1.7M
2016	502.0K	777.0K	1.0M	1.2M
2015	252.0K	226.0K	219.0K	219.0K
2014	700.0K	700.0K	617.0K	383.0K
2013	266.8K	383.5K	500.3K	617.0K
2012	0	0	0	150.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Revance Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	schilke tobin	sold	-47,203	5.0426	-9,361	cfo
Mar 18, 2024	sjuts dustin s	sold	-46,446	5.0425	-9,211	president
Mar 18, 2024	moxie dwight	sold	-40,971	5.0426	-8,125	clo & gc
Mar 15, 2024	sjuts dustin s	sold (taxes)	-15,739	5.305	-2,967	president
Mar 15, 2024	foley mark j	sold (taxes)	-108,928	5.305	-20,533	ceo
Mar 15, 2024	schilke tobin	sold (taxes)	-20,275	5.305	-3,822	cfo
Mar 15, 2024	moxie dwight	sold (taxes)	-17,342	5.305	-3,269	clo & gc
Mar 06, 2024	foley mark j	bought	209,400	6.98	30,000	ceo
Feb 29, 2024	moxie dwight	acquired	-	-	15,143	clo & gc
Feb 29, 2024	sjuts dustin s	acquired	-	-	22,110	president

Which funds bought or sold RVNC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	Legato Capital Management LLC	added	76.65	-5,698	501,063	0.06%
Apr 15, 2024	Future Financial Wealth Managment LLC	new	-	19,680	19,680	0.01%
Apr 12, 2024	Riverview Trust Co	new	-	15,926	15,926	0.01%
Apr 12, 2024	DNB Asset Management AS	added	38.6	-68,774	235,817	-%
Apr 12, 2024	BALDWIN BROTHERS LLC/MA	unchanged	-	-1,935	2,460	-%
Apr 10, 2024	DAYMARK WEALTH PARTNERS, LLC	added	58.62	-28,590	226,320	0.01%
Apr 10, 2024	Yarbrough Capital, LLC	unchanged	-	-47,225	60,039	-%
Apr 09, 2024	MATHER GROUP, LLC.	new	-	6,153	6,153	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	sold off	-100	-1,609	-	-%
Apr 05, 2024	GAMMA Investing LLC	reduced	-12.56	-857	5,068	-%

Are Funds Buying or Selling RVNC?

Are funds buying RVNC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RVNC

No. of Funds

RVNC Alerts

JPMORGAN CHASE & CO reported owning 2.6% of RVNC [2024-04-09]
1 major insider buys recently.

Unveiling Revance Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	jpmorgan chase & co	2.6%	2,768,691	SC 13G/A
Feb 14, 2024	antara capital lp	0%	0	SC 13G/A
Feb 14, 2024	palo alto investors lp	5.96%	5,237,284	SC 13G/A
Feb 13, 2024	polar capital holdings plc	3.60%	3,169,239	SC 13G/A
Feb 13, 2024	vanguard group inc	5.77%	5,069,625	SC 13G/A
Feb 09, 2024	gic private ltd	6.63%	5,825,881	SC 13G/A
Feb 09, 2024	capital world investors	13.6%	11,939,076	SC 13G/A
Feb 06, 2024	franklin resources inc	6.8%	6,108,277	SC 13G
Jan 25, 2024	jpmorgan chase & co	5.4%	4,754,771	SC 13G/A
Jan 25, 2024	blackrock inc.	8.5%	7,453,371	SC 13G/A

Recent SEC filings of Revance Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	SC 13G/A	Major Ownership Report
Mar 21, 2024	DEF 14A	DEF 14A
Mar 21, 2024	DEFA14A	DEFA14A
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 18, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Revance Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	-0.04%	-27.89%	-8.41	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.5B	1.8B	-1.63%	-28.69%	-42.01	10.12	76.23%	61.08%
BMRN	17.2B	2.4B	8.39%	-9.36%	102.31	7.09	15.42%	18.43%
INCY	11.9B	3.7B	-8.82%	-29.04%	20	3.23	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-8.69%	-36.86%	-11.82	15.75	425.83%	18.94%
BBIO	4.4B	-	-8.20%	68.33%	-6.81	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-8.92%	-2.36%	-13.62	12.04	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.30%	-24.47%	-9.88	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-11.77%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.36%	-14.10%	25.63	4.6	85.90%	-14.05%
NVAX	557.0M	983.7M	-24.76%	-57.93%	-1.02	0.57	-50.36%	17.16%
CRBP	432.8M	881.7K	-5.56%	294.36%	-9.7	466.16	-77.61%	-5.33%
INO	225.3M	4.9M	-10.24%	-14.54%	-1.67	46.29	-54.97%	51.72%
IBIO	6.8M	2.1M	86.67%	92.16%	-0.25	2.14	-13.45%	66.37%

Revance Therapeutics Inc News

Latest updates

Revance Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	22.9%	69,799,000	56,776,000	58,134,000	49,331,000	49,921,000	29,015,000	28,368,000	25,261,000	25,950,000	19,745,000	18,804,000	13,299,000	11,133,000	3,835,000	299,000	58,000	693,500	1,329,000	1,596,000	1,570,000	630,000
Operating Expenses	-36.9%	123,752,000	196,069,000	123,633,000	107,363,000	194,332,000	106,499,000	86,210,000	87,482,000	87,554,000	92,468,000	89,141,000	83,311,000	89,102,000	80,963,000	57,404,000	61,018,000	46,259,000	42,586,000	39,122,000	36,905,000	38,895,000
S&GA Expenses	23.4%	85,243,000	69,094,000	77,384,000	66,011,000	65,237,000	65,775,000	47,847,000	45,075,000	46,436,000	52,782,000	50,598,000	49,005,000	52,833,000	48,183,000	29,606,000	21,224,000	18,766,000	16,739,000	13,596,000	12,910,000	13,358,000
R&D Expenses	55.9%	20,366,000	13,060,000	22,807,000	23,177,000	19,541,000	26,103,000	24,913,000	30,729,000	29,468,000	30,095,000	29,441,000	27,251,000	29,768,000	29,130,000	27,103,000	39,794,000	27,493,000	25,847,000	25,526,000	23,995,000	25,537,000
EBITDA Margin	-	-	-	-	-	-	-	-2.69	-3.01	-3.49	-4.19	-	-9.37	-19.55	-30.54	-22.93	-21.17	-21.27	-22.31	-18.66	-	-
Interest Expenses	6.0%	5,398,000	5,093,000	4,368,000	4,497,000	3,752,000	6,917,000	3,874,000	1,931,000	1,573,000	1,571,000	1,569,000	1,560,000	4,410,000	4,334,000	4,256,000	2,148,000	-	-	-	-	-
Income Taxes	-100.0%	-	300,000	-	-	-	700,000	-	-	-	-	-	-	-2,720,000	-	-	100,000	-	-	-	-	3,000,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-74,376,000	-	-	-	-81,257,000	-	-	-	-	-	-	-
EBT Margin	-	-	-	-	-	-	-	-3.00	-3.31	-3.82	-4.63	-	-10.27	-21.21	-32.27	-25.01	-22.11	-21.80	-22.86	-19.11	-	-
Net Income	60.5%	-55,699,000	-141,176,000	-67,318,000	-59,793,000	-145,952,000	-84,693,000	-61,435,000	-64,342,000	-63,098,000	-74,376,000	-72,197,000	-71,639,000	-78,309,000	-81,257,000	-60,590,000	-61,933,000	-45,326,000	-41,409,000	-37,390,000	-35,304,000	-40,616,000
Net Income Margin	28.4%	-1.38	-1.93	-1.92	-2.25	-2.69	-2.52	-2.65	-3.05	-3.62	-4.71	-6.45	-10.21	-	-	-	-	-	-	-	-	-
Free Cashflow	19.8%	-44,510,000	-55,465,000	-53,116,000	-70,370,000	-31,470,000	-58,873,000	-43,689,000	-62,726,000	-48,968,000	-54,169,000	-49,985,000	-78,791,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-10.1%	478	532	598	548	582	712	562	640	531	582	641	676	720	712	576	593	340	266	296	324	226
Current Assets	-12.8%	339	389	379	323	375	416	261	285	246	294	355	406	450	450	503	518	297	221	250	277	208
Cash Equivalents	-23.4%	137	179	141	137	109	110	75.00	204	116	132	171	253	337	341	365	287	172	60.00	91.00	66.00	74.00
Inventory	-1.4%	46.00	46.00	34.00	28.00	18.00	17.00	14.00	11.00	10.00	10.00	5.00	6.00	6.00	4.00	1.00	-	-	-	-	-	-
Net PPE	0.3%	17.00	17.00	13.00	14.00	14.00	23.00	23.00	23.00	25.00	22.00	21.00	21.00	17.00	15.00	14.00	14.00	15.00	15.00	15.00	15.00	14.00
Goodwill	-	-	-	77.00	77.00	77.00	147	147	147	147	147	147	147	147	145	-	-	-	-	-	-	-
Liabilities	-1.4%	630	639	571	574	569	566	565	614	463	462	455	432	346	339	320	285	115	115	107	103	81.00
Current Liabilities	8.6%	89.00	82.00	74.00	78.00	76.00	75.00	77.00	71.00	67.00	66.00	58.00	51.00	61.00	64.00	48.00	42.00	41.00	34.00	45.00	34.00	32.00
Long Term Debt	-0.1%	427	427	380	380	379	379	378	90.00	281	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	100.0%	3.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-0.1%	427	427	-	-	379	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-151	-	27.00	-	13.00	146	0.00	26.00	68.00	120	1,447	244	374	373	0.00	0.00	225	151	0.00	221	146
Retained Earnings	-3.9%	-2,078	-2,000	-1,881	-1,814	-1,754	-1,600	-1,500	-1,500	-1,397	-1,334	-1,260	-1,200	-1,126	-1,050	-966	-906	-844	-798	-757	-720	-684
Additional Paid-In Capital	0.5%	1,927	1,916	1,908	1,788	1,767	1,755	1,521	1,488	1,466	1,455	1,447	1,432	1,501	1,421	1,222	1,214	1,070	950	946	941	830
Shares Outstanding	0.2%	88.00	88.00	88.00	84.00	82.00	82.00	73.00	72.00	68.00	72.00	72.00	71.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	2,200	-	-	-	1,000	-	-	-	2,000	-	-	-	1,400	-	-	-	494	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	16.2%	-42,731	-50,962	-53,382	-69,500	-30,182	-57,871	-44,225	-61,270	-44,611	-53,167	-49,005	-74,755	-62,314	-55,686	-17,213	-43,289	-33,508	-31,949	-29,290	-11,414	-31,141
Share Based Compensation	-14.0%	8,845	10,287	15,599	13,082	10,727	17,987	9,263	14,363	10,921	10,538	11,368	10,607	11,879	10,677	7,353	6,544	5,040	4,303	4,420	4,159	3,851
Cashflow From Investing	-95.4%	2,370	51,586	-39,532	95,316	40,960	-118,445	-105,881	44,568	27,641	16,807	-35,693	-38,420	-8,691	32,496	93,895	-105,569	30,919	918	54,012	-103,441	59,101
Cashflow From Financing	-104.3%	-1,629	37,460	97,471	3,265	-6,173	211,389	21,165	105,313	405	-2,492	2,912	29,044	67,324	-687	500	264,347	114,827	-81.00	43.00	106,868	164

RVNC Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 234,040	$ 132,565	$ 77,798
Operating expenses:
Selling, general and administrative	297,732	223,934	198,821
Research and development	79,410	101,286	116,255
Goodwill impairment	77,175	69,789	0
Intangible asset impairment	16,007	0	0
Amortization	6,130	27,847	13,988
Total operating expenses	550,817	474,523	352,474
Loss from operations	(316,777)	(341,958)	(274,676)
Interest income	13,285	4,891	337
Interest expense	(19,356)	(16,474)	(6,273)
Other expense, net	(838)	(2,181)	(698)
Loss before income taxes	(323,686)	(355,722)	(281,310)
Income tax provision	(300)	(700)	0
Net loss	(323,986)	(356,422)	(281,310)
Unrealized gain (loss)	388	(356)	(18)
Comprehensive loss	(323,598)	(356,778)	(281,328)
Basic net loss	(323,986)	(356,422)	(281,310)
Diluted net loss	$ (323,986)	$ (356,422)	$ (281,310)
Basic net loss per share (in dollars per share)	$ (3.83)	$ (4.90)	$ (4.17)
Diluted net loss per share (in dollars per share)	$ (3.83)	$ (4.90)	$ (4.17)
Basic weighted-average number of shares used in computing net loss per share (in shares)	84,599,409	72,713,340	67,507,818
Diluted weighted-average number of shares used in computing net loss per share (in shares)	84,599,409	72,713,340	67,507,818
Product revenue
Revenue:
Total revenue	$ 212,658	$ 118,131	$ 70,820
Operating expenses:
Cost of product revenue /service revenue (exclusive of depreciation and amortization)	62,335	44,414	23,125
Service revenue
Revenue:
Total revenue	12,249	6,990	1,323
Operating expenses:
Cost of product revenue /service revenue (exclusive of depreciation and amortization)	12,028	7,253	285
Collaboration revenue
Revenue:
Total revenue	$ 9,133	$ 7,444	$ 5,655

RVNC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 137,329	$ 108,965
Restricted cash, current	550	0
Short-term investments	116,586	231,742
Accounts receivable, net	27,676	11,339
Inventories	45,579	18,325
Prepaid expenses and other current assets	11,145	4,356
Total current assets	338,865	374,727
Property and equipment, net	17,225	13,799
Goodwill	0	77,175
Intangible assets, net	9,808	35,344
Operating lease right-of-use assets	53,167	39,223
Finance lease right-of-use asset	19,815	6,393
Restricted cash, non-current	6,870	6,052
Finance lease prepaid expense	32,383	27,500
Other non-current assets	321	1,687
TOTAL ASSETS	478,454	581,900
CURRENT LIABILITIES
Accounts payable	13,809	4,546
Accruals and other current liabilities	53,824	59,357
Deferred revenue, current	10,737	6,867
Finance lease liability, current	2,651	669
Operating lease liabilities, current	5,703	4,243
Debt, current	2,500	0
Total current liabilities	89,224	75,682
Debt, non-current	426,595	379,374
Deferred revenue, non-current	70,419	78,577
Operating lease liabilities, non-current	40,985	34,182
Other non-current liabilities	2,835	1,485
TOTAL LIABILITIES	630,058	569,300
Commitments and Contingencies (Note 15)
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, par value $0.001 per share — 190,000,000 shares authorized as of December 31, 2023 and 2022; 87,962,765 and 82,385,810 shares issued and outstanding as of December 31, 2023 and 2022, respectively	88	82
Additional paid-in capital	1,926,654	1,767,266
Accumulated other comprehensive gain (loss)	14	(374)
Accumulated deficit	(2,078,360)	(1,754,374)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	(151,604)	12,600
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 478,454	$ 581,900

About Revance Therapeutics Inc

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

CEO	Mr. Mark J. Foley
WEBSITE	revance.com
INDUSTRY	Biotechnology
EMPLOYEES	534

Revance Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Revance Therapeutics Inc? What does RVNC stand for in stocks?

RVNC is the stock ticker symbol of Revance Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Revance Therapeutics Inc (RVNC)?

As of Tue Apr 16 2024, market cap of Revance Therapeutics Inc is 336.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVNC stock?

You can check RVNC's fair value in chart for subscribers.

What is the fair value of RVNC stock?

You can check RVNC's fair value in chart for subscribers. The fair value of Revance Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Revance Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RVNC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Revance Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RVNC is over valued or under valued. Whether Revance Therapeutics Inc is cheap or expensive depends on the assumptions which impact Revance Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVNC.

What is Revance Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, RVNC's PE ratio (Price to Earnings) is -1.04 and Price to Sales (PS) ratio is 1.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RVNC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Revance Therapeutics Inc's stock?

In the past 10 years, Revance Therapeutics Inc has provided -0.182 (multiply by 100 for percentage) rate of return.